SNY - Sanofi

NasdaqGS - NasdaqGS Real-time price. Currency in USD
45.95
-0.27 (-0.58%)
At close: 4:00PM EST

46.69 +0.74 (1.61%)
Pre-market: 8:14AM EST

Stock chart is not supported by your current browser
Previous close46.22
Open46.07
Bid46.65 x 1100
Ask46.69 x 1800
Day's range45.67 - 46.21
52-week range40.00 - 47.47
Volume858,028
Avg. volume1,442,453
Market cap115.041B
Beta (3Y monthly)0.48
PE ratio (TTM)23.69
EPS (TTM)1.94
Earnings dateN/A
Forward dividend & yield1.74 (3.79%)
Ex-dividend date2019-05-07
1y target est52.00
  • Amarin's Shares Down on Underperform Rating by Oppenheimer
    Zacks

    Amarin's Shares Down on Underperform Rating by Oppenheimer

    Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.

  • Sanofi weighing options for consumer healthcare unit: sources
    Reuters

    Sanofi weighing options for consumer healthcare unit: sources

    FRANKFURT/PARIS (Reuters) - Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. Recently appointed chief executive Paul Hudson, who took the job on Sept. 1, plans to meet investors for a capital markets day in Cambridge, Massachusetts, on Dec. 10.

  • Sanofi weighing options for consumer healthcare unit - sources
    Reuters

    Sanofi weighing options for consumer healthcare unit - sources

    FRANKFURT/PARIS (Reuters) - Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. Recently appointed chief executive Paul Hudson, who took the job on Sept. 1, plans to meet investors for a capital markets day in Cambridge, Massachusetts, on Dec. 10.

  • Reuters - UK Focus

    Sanofi weighing options for consumer healthcare unit-sources

    FRANKFURT/PARIS, Nov 21 (Reuters) - Sanofi is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month. An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. Sources cautioned that no final decision had been made.

  • A $5 Billion Cholesterol Bet May Be an Overreach
    Bloomberg

    A $5 Billion Cholesterol Bet May Be an Overreach

    (Bloomberg Opinion) -- Novartis AG appears ready to put a premium on convenience.Bloomberg News reported early Tuesday that the Swiss pharmaceutical giant is conducting due diligence on Medicines Co., a New Jersey-based biotechnology company with a promising drug called inclisiran that can substantially lower so-called bad cholesterol with just two annual treatments. Its principal rivals, Amgen Inc.'s Repatha, and Sanofi and Regeneron Pharmaceutical Inc.’s Praluent, require biweekly or monthly injections. Buying Medicines Co. wouldn’t be a megadeal, but it won’t come cheap. The company’s share price had already more than tripled this year as it released promising data, and a 20% boost prompted by deal speculation Tuesday pushed its market value well above $5 billion. If the price gets too high or the unnamed others reportedly also interested in the company start a bidding war, Novartis should be ready to walk away. Despite its promise, inclisiran also has its potential limits, and its sales potential is still highly uncertain. Approval isn’t expected until next year.Inclisiran’s predecessors Repatha and Praluent launched with much fanfare in 2015, and the assumption was that they would take on blockbuster status. Insurers balked at the high price of the drugs and the potentially massive market of patients with high cholesterol who might want it, and threw up barriers to access. As a result, the medicines got off to a slow sales start and continue to struggle. Both companies hoped that large outcomes trials proving that the drugs could prevent events such as heart attacks and strokes would turn things around and boost sales. The benefit wasn’t as significant as some hoped, and major sales acceleration never arrived. After a series of big price cuts, the drugs now cost under $6,000, less than half their list price at launch. The two drugs are expected to combine for around $940 million in sales this year; analysts once expected the two to have surpassed that on their own by now. Inclirisan works in a different way and looks like a more effective drug, able to lower cholesterol at a similar rate without nearly as many jabs of the needle. That’s better for patients, and physicians are likely to prefer it because that could translate to fewer missed doses and potentially better overall results. Patients and physicians don't get to choose on their own, though: Price-conscious health plans, insurers, and pharmacy benefit managers are the real decision-makers.These groups are pretty comfortable limiting the use of more expensive next-generation cholesterol drugs to a relatively small population. That reality and the ever-decreasing price of Praluent and Repatha suggests that inclisiran may have trouble pricing at much of a premium.  The drug’s convenience and impact may finally expand this market to a broader group of Americans, especially if its owner is willing to compromise on cost at launch or an outcomes trial due in a few years reveals a positive surprise. It’s entirely possible, however, that it ends up with just a corner of a market that never gets all that big. Under the stewardship of a big company like Novartis, which has managed to navigate a slow launch and resistant market pretty well for its own heart drug Entresto, inclirisan is likely to deliver at least respectable sales some day. The company should be cautious if the price gets to a point where respectable won’t be nearly enough. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Protalix Finalizes Accelerated Approval Pathway for PRX-102
    Zacks

    Protalix Finalizes Accelerated Approval Pathway for PRX-102

    Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

  • The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's
    Zacks

    The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's

    The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's

  • Top Stock Reports for Chevron, HSBC & Sanofi
    Zacks

    Top Stock Reports for Chevron, HSBC & Sanofi

    Top Stock Reports for Chevron, HSBC & Sanofi

  • Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
    Zacks

    Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

    Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.

  • Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study
    Zacks

    Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

    GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

  • Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus
    Zacks

    Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

    Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

  • The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
    Zacks

    The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

    The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

  • Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
    Zacks

    Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

    Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

  • Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
    Zacks

    Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

    Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

  • Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength
    Zacks

    Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength

    Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

  • Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
    Zacks

    Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

    Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

  • Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates
    Zacks

    Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates

    Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

  • Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales
    Zacks

    Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales

    Sanofi (SNY) reports mixed third-quarter results with strong Specialty Care sales but soft Vaccines & Consumer Healthcare sales.

  • Bloomberg

    Sanofi Profit Beats Estimates With New CEO Hudson at Helm

    (Bloomberg) -- Sanofi’s key growth driver, a drug for eczema and asthma, helped the French pharma giant report earnings that beat analysts’ estimates in Paul Hudson’s first quarter as chief executive officer.Earnings excluding some items climbed 4.3% to 1.92 euros a share in the quarter. Analysts predicted earnings of 1.72 euros a share. The company reiterated its forecast of 5% growth for the year.Key InsightsSanofi’s new chief, who took the reins last month, will face questions on the future of the company’s consumer-health and diabetes units, R&D priorities and M&A plans. An experimental cancer combination was stopped in the quarter for efficacy reasons, along with an early-stage treatment for obesity and diabetes, Sanofi said. Hudson is expected to accelerate efforts to revamp the pipeline in the coming months.The hemophilia medicine Eloctate will be in focus after disappointing results pushed the drugmaker in July to curtail sales projections and announce a 1.8 billion-euro ($2 billion) charge.Market PerformanceThe stock rose as much as 1.7% in early Paris trading. The shares have gained about 12% so far this year, compared with a 20% gain in the Bloomberg Europe 500 Pharmaceuticals Index.Get MoreRead more details.See the statement.(Updates with share price in market performance section.)To contact the reporter on this story: James Paton in London at jpaton4@bloomberg.netTo contact the editors responsible for this story: Eric Pfanner at epfanner1@bloomberg.net, Marthe Fourcade, Frank ConnellyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Sanofi confident for 2019 despite third-quarter sales slip
    Reuters

    Sanofi confident for 2019 despite third-quarter sales slip

    Sanofi expressed confidence for the fourth quarter and confirmed its full-year objectives on Thursday after posting lower third-quarter sales, hit by a fall in revenue at its primary care and vaccines businesses. Shares in Sanofi were down 1.6% at 83.89 euros by 1430 GMT, underperforming a 0.16% drop in the wider market . "Focus remains on the Dec 10 capital markets day," Jefferies analysts wrote in a note to clients, at which the group's newly appointed chief executive Paul Hudson is expected to unveil Sanofi's middle and long term strategy.

  • Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More
    Zacks

    Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

    Key highlights include earnings updates, collaboration deals, and regulatory and pipeline updates.

  • Reuters - UK Focus

    RPT-Ex-FDA chief Gottlieb sees investment opportunity in 'unloved' antibiotics

    As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. Since leaving the FDA in April, Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates, one of the country's largest venture capital firms where he worked prior to his time in government. Near the top of his list are companies researching new kinds of antibiotics, an issue he advocated for while at the FDA.

  • Is a Beat in Store for Amarin (AMRN) This Earnings Season?
    Zacks

    Is a Beat in Store for Amarin (AMRN) This Earnings Season?

    Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

  • The Sanofi (EPA:SAN) Share Price Is Up 18% And Shareholders Are Holding On
    Simply Wall St.

    The Sanofi (EPA:SAN) Share Price Is Up 18% And Shareholders Are Holding On

    Investors can buy low cost index fund if they want to receive the average market return. But if you invest in...

  • Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?

    Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more